Boehringer submits MAA for nintedanib

Boehringer Ingelheim GmbH (Ingelheim, Germany) submitted an MAA to EMA for nintedanib in combination with docetaxel for second-line treatment of advanced, metastatic or recurrent non-small cell lung c...